BLCO Earnings Date: Feb 17, 2027 (Estimated) — Bausch + Lomb Corporation
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is BLCO's next earnings date?
Bausch + Lomb Corporation (BLCO) is expected to report Q4 2026 earnings on Wednesday, February 17, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.35 on revenue of $1.49B.
How did BLCO do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Bausch + Lomb Corporation posted EPS of $0.34 versus the $0.21 estimate, a beat of 58.5%. Revenue was $1.37B against a $1.37B estimate. The stock's 1-day post-earnings move was +15.8%.
How much does BLCO stock move after earnings?
BLCO beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.7% (up or down) in the day after earnings.
About Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
🤖 AI Earnings Analysis
Bausch & Lomb’s Q3 was mixed: EPS of $0.34 beat estimates by $0.13, but revenue of $1.4B missed. The earnings beat is encouraging, though modest sales growth tempers confidence in healthcare-device demand.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 0.21 | 0.34 | +58.51% | $1.37B | ✅ Beat | +15.78% | — | — |
| 2026-07-29 | Q2 2026 | 0.16 | 0.16 | +0.00% | $1.39B | ➖ Inline | -2.47% | +0.42% | +3.85% |
| 2026-04-29 | Q1 2026 | 0.05 | 0.08 | +60.00% | $1.24B | ✅ Beat | -2.42% | +1.78% | -0.83% |
| 2026-02-18 | Q4 2025 | 0.35 | 0.32 | -8.57% | $1.41B | ❌ Miss | -0.34% | +4.00% | -9.64% |
| 2025-10-29 | Q3 2025 | 0.16 | 0.18 | +12.50% | $1.28B | ✅ Beat | +1.78% | -1.32% | +6.58% |
| 2025-07-30 | Q2 2025 | 0.07 | 0.07 | +0.00% | $1.28B | ➖ Inline | -6.42% | -1.43% | -0.68% |
| 2025-04-30 | Q1 2025 | 0.02 | -0.07 | -450.00% | $1.14B | ❌ Miss | -15.74% | -20.55% | -14.58% |
| 2025-02-19 | Q4 2024 | 0.24 | 0.25 | +4.17% | $1.28B | ✅ Beat | -0.31% | -2.32% | -5.26% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $1.38B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Device Products | 37.6% | $517.0M | +6.8% | $448.0M | $472.0M | $484.0M | $518.0M |
| Over the Counter Products | 34.7% | $477.0M | +5.1% | $409.0M | $482.0M | $454.0M | $489.0M |
| Pharmaceutical Products | 23.2% | $319.0M | +13.9% | $222.0M | $260.0M | $280.0M | $319.0M |
| Branded and Other Generic Products | 4.2% | $58.0M | -1.7% | $54.0M | $58.0M | $59.0M | $72.0M |
| Other Revenues | 0.3% | $4.0M | 0.0% | $4.0M | $6.0M | $4.0M | $7.0M |
By region
Q4 FY24 · $1.25B total
| Segment | Share | Revenue | YoY | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 |
|---|---|---|---|---|---|---|---|
| United States and Puerto Rico | 52.6% | $657.0M | +10.8% | $466.0M | $471.0M | $593.0M | $537.0M |
| Other Countries | 19.6% | $244.0M | +14.0% | $152.0M | $150.0M | $214.0M | $166.0M |
| CHINA | 7.7% | $96.0M | +2.1% | $89.0M | $87.0M | $94.0M | $77.0M |
| FRANCE | 4.1% | $51.0M | +13.3% | $62.0M | $47.0M | $45.0M | $60.0M |
| JAPAN | 4.0% | $50.0M | +4.2% | $46.0M | $45.0M | $48.0M | $42.0M |
| CANADA | 2.7% | $34.0M | +13.3% | $27.0M | $27.0M | $30.0M | $28.0M |
| GERMANY | 2.6% | $32.0M | 0.0% | $40.0M | $33.0M | $32.0M | $42.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.